Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin for Rubeosis Iridis in Ischemic CRVO
NCT00557232Phase 4Completed
- Sponsor
- Instituto de Olhos de Goiânia
- Start
- Nov 2006
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label trial of bevacizumab in rubeosis iridis (NVI) and neovascular glaucoma (NVG), sponsored by Instituto de Olhos de Goiânia. Primary endpoint: Incidence of Rubeosis Iridis at 12 months. Started Nov 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
rubeosis iridis (NVI)neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT00557232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557232.